All > Scar

Vital sign measurements for Diffuse Large B-cell Lymphoma

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Diffuse Large B-cell Lymphoma+1 MoreVital sign measurements - Procedure
Eligibility
18 - 75
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test if a new cancer treatment can be given safely to patients outside of a hospital.

Eligible Conditions
  • Diffuse Large B-cell Lymphoma
  • Non-Hodgkin's Lymphoma

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
Duvelisib
1
EZM0414
1
Polymer-conjugated IL-15 Receptor Agonist NKTR-255

Study Objectives

2 Primary · 4 Secondary · Reporting Duration: at 30 days

Approximately 30 days
Calculate cost of administering YESCARTA in the out-patient setting
Count of risk factors that preclude out-patient administration of YESCARTA
Measure cumulative steroid exposure
Measure effectiveness of close monitoring of participants in the out-patient setting
Approximately 6 weeks
Feasibility of treating participants with YESCARTA in the out patient setting
at 30 days
Measure time to specific interventions post infusion

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
Duvelisib
1
EZM0414
1
Polymer-conjugated IL-15 Receptor Agonist NKTR-255

Trial Design

1 Treatment Group

YESCARTA in the Outpatient Setting
1 of 1

Experimental Treatment

20 Total Participants · 1 Treatment Group

Primary Treatment: Vital sign measurements · No Placebo Group · N/A

YESCARTA in the Outpatient SettingExperimental Group · 5 Interventions: Vital sign measurements, Telemedicine Visit, Visit from Home Health Nurse, Out-Patient Clinic Visit, Blood pressure and pulse oximeter · Intervention Types: Procedure, Procedure, Procedure, Procedure, Procedure
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Telemedicine Visit
2017
N/A
~20

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: at 30 days

Who is running the clinical trial?

Vanderbilt-Ingram Cancer CenterLead Sponsor
202 Previous Clinical Trials
65,481 Total Patients Enrolled
Kite, A Gilead CompanyIndustry Sponsor
30 Previous Clinical Trials
3,129 Total Patients Enrolled
Olalekan Oluwole, MDPrincipal InvestigatorVanderbilt-Ingram Cancer Center

Eligibility Criteria

Age 18 - 75 · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have a diagnosis of CLL/SLL and are eligible for leukapheresis.
You have two lines of therapy, one of which includes an anthracycline and a CD20-targeted therapy, and you have failed both of them.
Creatinine clearance ≥ 60 mL/min/1.73 m2.
You have a cardiac ejection fraction of 50% or more.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top